Asundexian is an investigational oral Factor XIa inhibitor.
Your search for apixaban returned 51 results
Abelacimab is a highly selective, fully human monoclonal antibody designed to inhibit both factor XI and its activated form, factor XIa.
Findings may help with decision-making in this high-risk patient population.
Study findings revealed an increased risk of surgical intervention in women exposed to rivaroxaban.
Concomitant use of dabigatran with verapamil or diltiazem was found to be associated with an increased risk of bleeding in patients with normal kidney function, according to the findings of a recently published retrospective cohort study.
A recent report published in the New England Journal of Medicine describes the case of a patient with persistent skin discoloration associated with the use of the antiarrhythmic agent amiodarone. The 81-year-old man presented to the emergency department after a fall, which was eventually attributed to orthostatic hypotension. His medical history included atrial fibrillation and…
A list of medications routinely prescribed in primary care practice that should be used cautiously or avoided in patients with chronic kidney disease (CKD) was compiled in a recently published study in the Annals of Pharmacotherapy.
The Food and Drug Administration (FDA) has approved the first generics of Eliquis (apixaban; Bristol-Myers Squibb and Pfizer) tablets. Apixaban, a factor Xa inhibitor, is indicated: To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism…
According to the findings of a recent study, attorney advertisements appear to influence patients’ decisions on modifying or discontinuing their direct oral anticoagulant (DOAC) medication prior to seeking medical advice.
Results from the phase 4 AUGUSTUS trial, evaluating apixaban vs vitamin K antagonists in patients with nonvalvular atrial fibrillation and recent acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention.